% study characteristics

\begin{landscape}
    % \singlespacing
    \begin{table}[htbp]
        \footnotesize
        \begin{tabular}{@{} L{3.1cm} L{2.1cm} L{2cm} L{1.7cm} L{6cm} L{6cm} @{}}
            \toprule
            Study                                        & Location                               & Treatment                 & n (relapse) \%     & Significant predictors -- univariable                                                                                                                                                                                                          & Significant predictors -- multivariable                                                                                                                                                          \\
            \midrule
            \textbf{ISC}                                 &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \hspace{0.5em}Burza 2014\cite{burza2014}     & MSF clinics, Bihar, India              & 20mg/kg LAMB (4 x 5mg/kg) & 8,537~(119) 13.9\% & age < 5****, age $\geq$ 45** vs. 15--30~yrs; male sex***; other backwards caste* vs. general category; symptom duration\footnotemark[1] > 8 wks***, > 4 to $\leq$ 8wks** vs. $\leq$~4 wks; spleen size change $\leq$~0.5cm/day vs. >~0.5cm/day & age~<~5****, age~$\geq$~45** vs. 15--30 yrs; male sex***; symptom duration\footnotemark[1] >~8~wks**, >~4 to~$\leq$~8wks** vs. $\leq$~4 wks; spleen size change $\leq$~0.5cm/day vs.~>~0.5cm/day \\
            \hspace{0.5em}Goyal 2019\cite{goyal2019}     & Public health facilities, Bihar, India & SDA; LAMB+MF; MF+PM       & 1,353 (75) 5.5\%   & treatment****; age 2--12~yrs** vs. > 12~yrs; symptom duration $\leq$~8~wks*** vs. >~8 wks                                                                                                                                                      & treatment MF+PM$^{\dagger}$ vs. SDA; age 2--12~yrs$^{\dagger}$ vs. > 12~yrs;  symptom duration $\leq$~8~wks$^{\dagger}$ vs. >~8 wks                                                              \\
            \hspace{0.5em}Goyal 2020\cite{goyal2020}     & [as above]                             & [as above]                & 1,750 (79) 4.5\%   & age 2--12~yrs$^{\dagger\dagger}$ vs. > 12~yrs; treatment with MF+PM$^{\dagger\dagger}$                                                                                                                                                         & treatment MF+PM**** vs. SDA; age 2--12~yrs*** vs > 12~yrs; symptom duration $\leq$~8~wks*** vs. >~8 wks                                                                                          \\
            \hspace{0.5em}Lucero 2015\cite{lucero2015}   & MSF clinic, Fulbaria, Bangladesh       & 15mg/kg LAMB (3 x 4mg/kg) & 1,521 (39) 2.6\%   & age <~5~yrs***, age~$\geq$~40 yrs** vs. 18--39~yrs; lower admission Hb***; lower discharge Hb***; larger discharge spleen size***                                                                                                              & age <~5~yrs***, age~$\geq$~40 yrs** vs. 18--39~yrs; larger discharge spleen size**                                                                                                               \\
            \hspace{0.5em}Mondal 2019\cite{mondal2019}   & Hospital in Mymensingh, Bangladesh.    & 8 different regimens      & 984 (69) 7.0\%.    & treatments compared only: MD-LAMB*, MF**, LAMB+PM**, LAMB+MF***, SDA****, PM****, MF+PM**** vs. SSG                                                                                                                                            & treatment\footnotemark[2]: MD-LAMB*, MF**, LAMB+PM**, SDA***, LAMB+MF****, PM****, MF+PM**** vs. SSG                                                                                             \\
            \hspace{0.5em}Ostyn 2014\cite{ostyn2014}     & Hospitals and clinics in Bihar, India  & MF                        & 853 (78) 9.1\%     & age 10--14 yrs***, 2--9 yrs**** vs. $\geq$25; male sex**                                                                                                                                                                                       & age 10--14 yrs***, 2--9 yrs**** vs. $\geq$25; male sex***                                                                                                                                        \\
            \hspace{0.5em}Rijal 2013\cite{rijal2013}     &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \hspace{0.5em}Sundar 2019\cite{sundar2019}   &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \textbf{East Africa}                         &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \hspace{0.5em}Gorski 2010\cite{gorski2010}   &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \hspace{0.5em}Kennedy 2024\cite{kennedy2024} &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \textbf{Mediterranean}                       &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \hspace{0.5em}Kajaia 2011\cite{kajaia2011}   &                                        &                           &                    &                                                                                                                                                                                                                                                &                                                                                                                                                                                                  \\
            \bottomrule
        \end{tabular}
        \label{tab:relapse-rf}
        \caption{Summary of studies predictors of VL relapse in immunocompetent patients. Excluding: studies only looking at treatment regimen or biomarkers. ****p < 0.001; ***0.001 $\leq$ p < 0.01; **0.01 $\leq$ p < 0.05; *0.05 $\leq$ p < 0.1; $^{\dagger}$p < 0.05 inferred as confidence interval does not cover null; ; $^{\dagger\dagger}$Significance level not stated; ISC: Indian subcontinent; MSF: Médecins Sans Frontières; Hb: haemoglobin; LAMB: liposomal amphotericin B; MF: miltefosine; PM: paromomycin; SDA: single dose liposomal amphotericin B 10mg/kg; SSG: sodium stibogluconate; VL: visceral leishmaniasis; wks: weeks; yrs: years.\\\textsuperscript{1}Shorter symptom duration associated with higher relapse risk in Burza 2014.\\\textsuperscript{2}Mondal 2019 included as multivariable adjusted for 10 other predictors, including age and sex, but these were not significant.}
    \end{table}
\end{landscape}

